AstraZeneca has established an executive research and development committee that will relate research efforts between its own group and its recently acquired firm MedImmune, an approach that deviates from how Roche Holding controls its biotech firm, Genentech, which operates as an entirely separate entity. An AstraZeneca official believes that sharing more ideas with the biotech firm could provide positive results for the company compared with the Roche-Genentech model.

Related Summaries